Chronic Myelogenous Leukemia (CML) is a prevalent hematologic malignancy characterized by the malignant transformation of myeloid cells and their proliferation in the peripheral blood. The management of CML poses significant challenges, particularly in detecting and eradicating minimal residual disease, which is crucial for preventing relapse and improving survival outcomes. Traditional minimal residual disease detection methods, such as bone marrow aspiration, are invasive and have limitations which include the potential for sampling errors and false negatives. This study introduces a novel label-free microfluidic chip designed for the segregation and recovery of circulating leukemia cells, offering a non-invasive liquid biopsy approach with potential applications in precision medicine. Over July 2021 to October 2023, we recruited 56 CML patients across various disease stages and collected blood samples for analysis using our microfluidic device. The device demonstrated high efficacy in isolating circulating leukemia cells, with an optimal capture efficiency of 78% at a sample flow rate of 3 mL/h. Our results indicate that the microfluidic device can efficiently segregate and quantify circulating leukemia cells, providing a detailed understanding of CML progression and treatment response. The significant reduction in circulating leukemia cell counts in patients in complete remission highlights the device’s potential in monitoring treatment efficacy. Furthermore, the device’s sensitivity in detecting minimal residual disease could offer a more reliable prognostic tool for therapeutic decision-making in CML management.
慢性粒细胞白血病（CML）是一种常见的血液系统恶性肿瘤，其特征为髓系细胞恶性转化并在外周血中异常增殖。该疾病的治疗面临重大挑战，尤其在检测和清除微小残留病方面，这对预防复发和改善生存结局至关重要。传统的微小残留病检测方法（如骨髓穿刺）具有侵入性，且存在采样误差和假阴性等局限性。本研究开发了一种新型无标记微流控芯片，专为分离和回收循环白血病细胞而设计，提供了一种非侵入性的液体活检方法，在精准医疗领域具有潜在应用价值。2021年7月至2023年10月期间，我们招募了56名处于不同疾病阶段的CML患者，采集血液样本并使用该微流控装置进行分析。该装置在分离循环白血病细胞方面表现出高效性，在3 mL/h的样本流速下最佳捕获效率达78%。研究结果表明，该微流控装置能有效分离并量化循环白血病细胞，为理解CML疾病进展和治疗反应提供详细依据。完全缓解患者循环白血病细胞数量的显著降低，凸显了该装置在监测治疗效果方面的潜力。此外，该装置检测微小残留病的高灵敏度，有望为CML治疗决策提供更可靠的预后评估工具。
肿瘤(癌症)患者之家